AusPAR: Hydrochlorothiazide / Olmesartan medoxomil / Amlodipine (as besilate)

Related information

How to access a pdf or Word document

*Large file warning: Attempting to open large files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.

Australian Public Assessment Report

23 December 2013
AusPAR Details
AusPAR
AusPAR: Hydrochlorothiazide / Olmesartan medoxomil / Amlodipine (as besilate) (pdf, 917 KB)
AusPAR: Hydrochlorothiazide / Olmesartan medoxomil / Amlodipine (as besilate) (docx, 2 MB)
Attachment: Product Information: Hydrochlorothiazide / Olmesartan medoxomil / Amlodipine (as besilate) (pdf, 413 KB)
Attachment: Product Information: Hydrochlorothiazide / Olmesartan medoxomil / Amlodipine (as besilate) (docx, 290 KB)
Attachment: Extract from Clinical Evaluation Report: Product Information: Hydrochlorothiazide / Olmesartan medoxomil / Amlodipine (as besilate) (pdf, 2 MB)
Attachment: Extract from Clinical Evaluation Report: Product Information: Hydrochlorothiazide / Olmesartan medoxomil / Amlodipine (as besilate) (docx, 3 MB)
Active Ingredient
Hydrochlorothiazide / Olmesartan medoxomil / Amlodipine (as besilate)
Product Name
Sevikar HCT
Sponsor
Merck Sharp & Dohme (Australia) Pty Ltd
Submission Number
PM-2012-01550-3-3
Submission Type
New fixed dose combination
Decision
Approved
AusPAR Date
18 November 2013
Publication Date

23 December 2013
Tags: 
AusPARs
URL: 
https://www.tga.gov.au/node/894